VRTX Vertex Pharmaceuticals Incorporated
Healthcare$436.50+0.00%OpenMarket Cap: $110.79B
As of 2026-05-26
Valuation
P/E (TTM)
27.75
PEG
0.03
P/B
5.70
P/S
9.00
EV/EBITDA
20.59
DCF Value
$414.38
FCF Yield
3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
86.3%
Operating Margin
39.0%
Net Margin
35.4%
ROE
23.9%
ROA
16.4%
ROIC
17.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $2.99B | 86.8% | $1.14B | $1.03B | $— | — |
| Q4 null | $3.23B | 85.6% | $1.30B | $1.19B | $— | — |
| FY null | $12.07B | 85.0% | $4.76B | $3.95B | $— | — |
| Q3 null | $3.08B | 86.5% | $1.19B | $1.08B | $— | — |
| Q2 null | $2.96B | 86.3% | $1.15B | $1.03B | $— | — |
| Q1 null | $2.77B | 86.9% | $630.1M | $646.3M | $— | — |
| Q4 null | $2.91B | 85.5% | $1.03B | $913.0M | $— | — |
| FY null | $11.02B | 86.1% | $-232.9M | $-535.6M | $— | — |
| Q3 null | $2.77B | 85.8% | $1.12B | $1.05B | $— | — |
| Q2 null | $2.65B | 85.9% | $-3.51B | $-3.59B | $— | — |
| Q1 null | $2.69B | 87.3% | $1.14B | $1.10B | $— | — |
| Q4 2023 | $2.52B | 85.4% | $988.5M | $968.8M | $3.71 | — |